ArticleNature communications2022
Evolution and modulation of antigen-specific T cell responses in melanoma patients.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Review
- Mitigating negative data bias to enhance TCR-epitope binding and residue interaction prediction.Briefings in bioinformatics · 2026Article
- Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer.ImmunoHorizons · 2026Article
- Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma.Cell research · 2025Article
- Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer.Leukemia · 2025Article
- Overcoming impaired antigen presentation in tumor draining lymph nodes facilitates immunotherapy.bioRxiv : the preprint server for biology · 2025Article
- Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma.American journal of clinical dermatology · 2025Review
- Tumor-specific CD8 T cell characterization in HRCell reports. Medicine · 2025Article
- Article
- The Multifaceted Role of the IL-2 Cytokine Family in Melanoma: Mechanisms, Therapeutic Implications, and Immune Modulation.Journal of immunology research · 2025Review
- Lnc-H19-derived protein shapes the immunosuppressive microenvironment of glioblastoma.Cell reports. Medicine · 2024Article
- Article
- Immune responses and immunotherapeutic approaches in the treatment against cancer.Clinical & experimental metastasis · 2024Review
- Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.Molecular biomedicine · 2024Review
- Polyomavirus-positive Merkel cell carcinoma: the beginning of the beginning.The Journal of clinical investigation · 2024Article
- Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.Nature reviews. Clinical oncology · 2024Review
- Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma.Cell reports. Medicine · 2024Article
- Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case.Journal for immunotherapy of cancer · 2024Article
- Identification of apolipoprotein B-reactive CDR3 motifs allows tracking of atherosclerosis-related memory CD4Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
Abstract
Analyzing antigen-specific T cell responses at scale has been challenging. Here, we analyze three types of T cell receptor (TCR) repertoire data (antigen-specific TCRs, TCR-repertoire, and single-cell RNA + TCRαβ-sequencing data) from 515 patients with primary or metastatic melanoma and compare it to 783 healthy controls. Although melanoma-associated antigen (MAA) -specific TCRs are restricted to individuals, they share sequence similarities that allow us to build classifiers for predicting anti-MAA T cells. The frequency of anti-MAA T cells distinguishes melanoma patients from healthy and predicts metastatic recurrence from primary melanoma. Anti-MAA T cells have stem-like properties and frequent interactions with regulatory T cells and tumor cells via Galectin9-TIM3 and PVR-TIGIT -axes, respectively. In the responding patients, the number of expanded anti-MAA clones are higher after the anti-PD1(+anti-CTLA4) therapy and the exhaustion phenotype is rescued. Our systems immunology approach paves the way for understanding antigen-specific responses in human disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.